Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this observational study is to investigate the beneficial value of complementary surgery for appendiceal neuro-endocrine tumours in children.
.
Aim Current guidelines recommend complementary right-sided hemicolectomy for high-risk (pT2(with risk factors)/pT3) neuro-endocrine tumors (NET) of the appendix (based on adult studies). In contrast to adults, high-risk NET of the appendix in children seems to be a relatively benign disease with high disease-free survival (100% versus 70-80% in adults), but high quality data are lacking. Therefore these recommendations are now being questioned. We aim to investigate the value of complementary right-sided hemicolectomy for children with high-risk NET of the appendix. Ultimately leading to the development of a consensus guideline and solid information for patients/parents.
Plan of investigation In order to generate big data, an international historical cohort study is planned to compare complementary right-sided hemicolectomy with appendectomy alone for children with high-risk NET of the appendix. Results will be CONFIDENTIAL used by an international expert group to formulate treatment recommendations. Subsequently, these recommendations will be tested in an international Delphi study in order to develop a consensus guideline on the treatment of pediatric high-risk NET of the appendix.
Expected results The cohort study will generate high quality information on overall/disease-free survival, recurrence, complications, costs, and hr-QoL. Recommendations made will be tested in a Delphi study; not only on the beneficial value of complementary right-sided hemicolectomy, but also on follow-up protocols and preoperative work-up. Ultimately, an international consensus guideline that redefines low-risk and high-risk NET of the appendix will be developed, leading to global de-escalation and uniformity of treatment.
Relevance for childhood cancer Results are relevant for pediatric oncologists/surgeons/gastro-enterologists across the world, as redefining low-risk and high-risk patient groups, will lead to de-escalation of treatment. Furthermore, QoL of child and parents can be improved by reducing exposure to complications after complementary right-sided hemicolectomy, and by reducing the fear of recurrence by obtaining high-quality data to accurately inform patients and parents.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Disease free survival rate | defined as alive and free of recurrence of NET at telephone follow-up performed for this study purpose | cross-sectional design. follow-up will be done in 2023/2024 |
| Recurrence rate | defined as histopathologically proven metastasis/residual tumor at appendiceal stump of NET after a disease free period | cross-sectional design. follow-up will be done in 2023/2024 |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival rate | defined as alive at telephone follow-up performed for this study purpose | cross-sectional design. follow-up will be done in 2023/2024 |
| Complications directly related to primary and secondary treatment divided into major and minor complications according to Clavien-dindo. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
All patients treated for an appendiceal neuro endocrine tumour before the age of 18 during 1990 and 2020
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ramon R Gorter, MD PhD | Contact | 0205669111 | rr.gorter@amsterdamumc.nl | |
| Martine F Raphael, MD PhD | Contact | 0205669111 | m.raphael@amsterdamumc.nl |
| Name | Affiliation | Role |
|---|---|---|
| Ramon R Gorter, MD PhD | Amsterdam UMC, department of pediatric surgery | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Amsterdam UMC | Recruiting | Amsterdam-Zuidoost | Netherlands |
individual participant data will not be shared with other researchers. Collaborating institution will however enter participant data in a coded/pseudonimyzed manner in Castor EDC database.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
| D001063 | Appendiceal Neoplasms |
| ID | Term |
|---|---|
| D002430 | Cecal Neoplasms |
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Complications include, but are not limited to:
|
| cross-sectional design. follow-up will be done in 2023/2024 |
| Number of hospital readmission for complications related to treatment of NET | see title | cross-sectional design. follow-up will be done in 2023/2024 |
| Length of hospital stay | initial and total length of stay | cross-sectional design. follow-up will be done in 2023/2024 |
| number of imaging studies performed for follow-up of NET | ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), octreotide scintigraphy, PET-CT | cross-sectional design. follow-up will be done in 2023/2024 |
| Number of outpatient check-ups(regular visits / telephone call) for follow-up of NET | see title | cross-sectional design. follow-up will be done in 2023/2024 |
| Health related Quality of Life at follow-up moment for this study | measured by the PedsQL(generic) | cross-sectional design. follow-up will be done in 2023/2024 |
| Health related Quality of Life at follow-up moment for this study | measured by the QLQ-C30(generic) | cross-sectional design. follow-up will be done in 2023/2024 |
| Health related Quality of Life at follow-up moment for this study | measured by the QLQ-GINET-21 questionnaire(disease specific) | cross-sectional design. follow-up will be done in 2023/2024 |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D002429 | Cecal Diseases |
| D007410 | Intestinal Diseases |